[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extremity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extremity":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100651080","deep-optical-imaging-of-tissue-doit-100651080",false,"NCT07754500","Deep Optical Imaging of Tissue (DOIT)","Measurement and Imaging Capability of a Novel Medical Imaging Method, Ultrasound Optical Tomography, Based on Ultrasound and Laser Light in Human Tissue","DOIT","Inclusion Criteria:\n\n* Healthy individuals without systemic or skin-related conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy: Although the risk that laser illumination on the skin may affect the fetus is minimal, we will exclude pregnant research subjects for safety.\n* Skin diseases: Certain skin conditions can increase the risk of damage or complications when exposed to laser light, such as active rosacea, eczema, skin infections, or tattoos.\n* Medication: Some medications can increase the sensitivity of the skin to laser light or increase the risk of side effects. It is important to consider the person's medical history and any ongoing treatments.\n* Sunburn: Recent sun exposure of the skin may lead to increased sensitivity to laser light and can be more likely to experience discomfort or skin irritation\u002Fdamage. This can both affect the reliability of the study and increase the risk of injury to the research subjects.\n* History of keloid formation or scarring: People who have a history of excessive scarring may be more likely to react with greater skin irritation from the laser light.\n* For breast measurements only: History of breast cancer or surgery. In this project, we aim to map the UOT signal only in healthy breast tissue.",true,"ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","In medical imaging, X-ray-based methods are widely used, which means that patients are exposed to ionizing radiation. In addition, invasive tissue samples often need to be taken with biopsy needles to, for example, safely determine or rule out a cancer diagnosis. With this project, the investigators evaluate a light-based (optical) method combined with ultrasound that is completely harmless to humans, ultrasound-optical-tomography (UOT). UOT is predicted to be able to penetrate deeper into the body to measure functions and image tissues than was previously possible with other optical imaging methods.\n\nThe aim of this project is to explore the capabilities and safety of UOT regarding imaging depth and tissue property information in healthy participants, as a first step to understand the technology's capabilities and limitations.\n\nThe long-term goal, in future steps, is to develop the technology for clinical assessment of cancer-suspected lesions with a particular focus on breast cancer and for assessment of circulatory disorders in tissue.",[28,29,30,31],"Healthy Tissue","Muscles","Extremity","Breast",[33,34,35,36,37,38],"Optical Imaging","Tissue Oxygenation","Breast \u002F Breast Neoplasms","Hemoglobin","Photoacoustic Techniques","Healthy Volunteers","RECRUITING","2026-08-06",{"date":42,"type":43},"2026-08-10","ACTUAL",{"date":45,"type":43},"2025-11-25",{"date":47,"type":22},"2027-12",{"name":49,"class":50},"Lund University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100452168","phase-2-preoperative-imrt-with-anlotinib-and-penpulimab-for-localized-sarcoma-spare-01-100452168","NCT05167994","Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）","Preoperative Intensity-Modulated Radiotherapy (IMRT) Combined With Concurrent Anlotinib Hydrochloride and Penpulimab for Localized Extremity or Trunk Sarcoma","SPARE-01","Inclusion Criteria:\n\n* Age older than 18-yo\n* Histology proven soft tissue sarcoma of truncal or extremity, deemed appropriate for preoperative radiotherapy and conservative surgery by multidisciplinary discussion.\n* ECOG 0-3\n* Histology reviewed by reference pathologist\n* Lesion can be assessed\n* Can tolerate radiotherapy and Anlotinib\n* Agree contraception.\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* No gross tumor post-resection in other center.\n* Contraindications to Anlotinib, including allergic to Anlotinb, active bleeding, ulcer, enteric perforation, enteric obstruction, uncontrolled hypertension, Grade 3 to 4 cardiac insufficiency (per NYHA criteria), and severe hepatic or renal insufficiency (Grade 4), etc.\n* Dermatofibrosarcoma protuberans(DFSP), Desmoids, etc.\n* Benign histology\n* Secondary cancer within 5 years (except cervical carcinoma in situ or early-stage skin basal cell carcinoma)\n* STS can be cured by extensive operation alone.\n* Previous irradiation to the same area\n* Radiological evidence of distant metastases\n* Other contraindications, can't tolerate operation or other treatment needed in this study.\n* Neoadjuvant chemotherapy given or planned.",{"count":61,"type":22},30,[63],"PHASE2","To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride and Penpulimab for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.",[66,30,67,68,69,70],"Sarcoma,Soft Tissue","Trunk","Anlotinib","Intensity-modulated Radiotherapy","Major Wound Complications","2026-06-03",{"date":73,"type":43},"2026-06-04",{"date":75,"type":43},"2020-05-01",{"date":77,"type":22},"2027-12-31",{"name":79,"class":50},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]